Stahlie, Emma H. A. http://orcid.org/0000-0002-8691-289X
Franke, Viola http://orcid.org/0000-0002-0703-5092
Zuur, Charlotte L. http://orcid.org/0000-0002-1777-012X
Klop, Willem M. C. http://orcid.org/0000-0002-6333-971X
van der Hiel, Bernies http://orcid.org/0000-0001-8158-405X
Van de Wiel, Bart A. http://orcid.org/0000-0001-7716-3308
Wouters, Michel W. J. M. http://orcid.org/0000-0001-6173-0662
Schrage, Yvonne M. http://orcid.org/0000-0001-7065-514X
van Houdt, Winan J. http://orcid.org/0000-0002-2303-3468
van Akkooi, Alexander C. J. http://orcid.org/0000-0002-3262-6935
Article History
Received: 27 October 2020
Accepted: 20 December 2020
First Online: 28 January 2021
Compliance with ethics standards
:
: Winan van Houdt declares advisory board/consultancy agreement and research grant received from Amgen. Michel Wouters declares a research grant received from Novartis. Alexander van Akkooi declares advisory board/consultancy agreements for Bristol-Myers Squibb, Novartis, MSD – Merck, Merck – Pfizer, 4SC and Amgen and a research grant received from Bristol-Myers Squibb, Novartis and Amgen. All other others have no relevant financial or non-financial interests to disclose.
: No identifiable patient information has been published warranting individual consent from patients. The requirement for individual patient informed consent for the purpose of data collection and publication was waived as per the regulations covered under the respective institutional IRBs.
: The study was performed with the approval of the Institutional Review Board (IRB) Netherlands Cancer Institute – Antoni van Leeuwenhoek and in accordance with the declaration of Helskini.